Holen Sie sich die Stockscreener-App
7.78
1.27%
-0.10
Handel nachbörslich:
7.78
Schlusskurs vom Vortag:
$7.88
Offen:
$7.87
24-Stunden-Volumen:
173.50K
Relative Volume:
0.33
Marktkapitalisierung:
$168.10M
Einnahmen:
$73.62M
Nettoeinkommen (Verlust:
$-138.24M
KGV:
-1.186
EPS:
-6.56
Netto-Cashflow:
$-99.19M
1W Leistung:
-3.11%
1M Leistung:
+51.95%
6M Leistung:
-40.43%
1J Leistung:
-45.59%
1-Tages-Spanne:
$7.3512
$7.89
1-Wochen-Bereich:
$7.3512
$8.76
52-Wochen-Spanne:
$4.71
$17.80
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Vergleichen Sie ENTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
7.78 | 168.10M | 73.62M | -138.24M | -99.19M | -6.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
| 2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
| 2018-12-13 | Eingeleitet | Berenberg | Hold |
| 2018-06-06 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | Barclays | Underweight |
| 2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
(ENTA) Trading Advice - Stock Traders Daily
Market Watch Highlights: Enanta Pharmaceuticals Inc (ENTA) Ends on an Upturn Note at 8.30 - The Dwinnex
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.com - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to “Hold” at StockNews.com - Defense World
HC Wainwright Has Pessimistic Outlook of ENTA Q2 Earnings - MarketBeat
Enanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlook - MSN
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $17.25 - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Purchases $256,050.00 in Stock - MarketBeat
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to "Sell" at StockNews.com - MarketBeat
JMP Securities maintains Enanta stock with $21 target - MSN
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns - Yahoo Finance
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock - Yahoo Finance
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade - MSN
Insider Moves Spark Attention as Enanta Pharmaceuticals Soars 46% - Smartphone Magazine
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Market Outperform" Rating from JMP Securities - MarketBeat
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry - Simply Wall St
Enanta Pharmaceuticals’ (ENTA) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright maintains $18 target on Enanta shares, affirms Buy - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Quarterly Earnings Results - MarketBeat
Enanta Pharmaceuticals Advances in Virology and Immunology - TipRanks
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock By Investing.com - Investing.com South Africa
ENANTA Pharmaceuticals CEO Acquires 45,000 Shares - TradingView
Enanta Pharmaceuticals Inc. (ENTA) reports earnings - Quartz
ENANTA PHARMACEUTICALS INC SEC 10-Q Report - TradingView
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded by StockNews.com to “Sell” - Defense World
JMP Securities maintains Enanta stock with $21 target By Investing.com - Investing.com Australia
JMP Securities Reaffirms “Market Outperform” Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - Defense World
HC Wainwright Reiterates Buy Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - MarketBeat
The Analyst Verdict: Enanta Pharma In The Eyes Of 4 Experts - Benzinga
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot - Huron Daily Tribune
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 - BioSpace
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2024 - Marketscreener.com
Enanta Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Enanta Pharmaceuticals Inc-Aktie (ENTA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kieffer Tara Lynn | Chief Product Strategy Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
29,305 |
| Luu Brendan | Chief Business Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
36,047 |
| Rottinghaus Scott T. | Chief Medical Officer |
Dec 06 '24 |
Sale |
8.06 |
866 |
6,980 |
17,918 |
| Or Yat Sun | Chief Scientific Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
369,109 |
| MELLETT PAUL J | Chief Fin. & Admin Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
91,710 |
| Luly Jay R. | President and CEO |
Dec 06 '24 |
Sale |
8.06 |
5,142 |
41,445 |
801,638 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 15 '24 |
Option Exercise |
8.99 |
5,375 |
48,321 |
27,092 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 15 '24 |
Sale |
17.08 |
5,375 |
91,805 |
21,717 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 11 '24 |
Sale |
15.07 |
4,299 |
64,786 |
23,988 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 12 '24 |
Sale |
15.04 |
2,271 |
34,156 |
21,717 |
2.95%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):